Alvotech And Bioventure Celebrate Egyptian Adalimumab Nod

Partnered AVT02 Biosimilar Rival To Humira Approved As Adalimumab-EVA

 
• By Dave Wallace

Egypt has become the latest market in which Alvotech has received approval for its AVT02 biosimilar adalimumab rival to Humira. The product will be marketed by MENA partner Bioventure.

Syringe and vial labelled with Egyptian flag
Alvotech and Bioventure have celebrated an Egyptian biosimilar approval • Source: Shutterstock

More from Biosimilars

More from Products